MedTrace Logo

3 Limus Agent Eluting Stents With Different Polymer Coating

NCT00598676 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 2600

Last updated 2010-03-15

No results posted yet for this study

Summary

The aim of this study is to determine whether biodegradable polymer based rapamycin-eluting stent performs equal to permanent polymer based everolimus- and rapamycin-eluting stents regarding reduction of adverse cardiac events at one year.

Conditions

Interventions

DEVICE

biodegradable polymer Rapamycin-eluting stent

due to randomization, rapamycin-eluting stent with biodegradable polymer will be implanted

DEVICE

permanent polymer rapamycin-eluting stent (Cypher)

due to randomization, rapamycin-eluting stent with permanent polymer will be implanted

DEVICE

permanent polymer everolimus-eluting stent (Xience, Promus)

due to randomization, everolimus-eluting stent with permanent polymer will be implanted

Sponsors & Collaborators

  • Deutsches Herzzentrum Muenchen

    lead OTHER

Principal Investigators

  • Albert Schoemig, MD · Deutsches Herzzentrum Muenchen

  • Adnan Kastrati, MD · Deutsches Herzzentrum Muenchen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2009-03-31
Completion
2009-04-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00598676 on ClinicalTrials.gov